Tickwind
TodayOpportunitiesMarketsAI Chat
EN
Log inSign up
Tickwind

Read every tick. See where the market's blowing.

  • X
  • TelegramChinese
  • Newsletter

Product

  • Markets
  • Theme Zones
  • All stocks
  • Compare
  • Hot stocks
  • Opportunities
  • News
  • Discussion
  • Watchlist
  • What's new

Account

  • Settings
  • Newsletter
  • For writers
  • MCP server
  • Contact
  • Log in
  • Sign up
MarketsTheme ZonesAll stocksCompareHot stocksOpportunitiesNewsDiscussionWatchlistWhat's newSettingsNewsletterFor writersMCP serverContactLog inSign up

© 2026 Tickwind. Not investment advice.

Made for the curious investor.

Home/GLUE/Revenue

Monte Rosa Therapeutics, Inc. (GLUE) Revenue 2023–2025

Monte Rosa Therapeutics, Inc. (GLUE) annual revenue history from SEC filings — each fiscal year as reported, with year-over-year change.

$123.7MFY2025 · since FY2023: $0 → $123.7M
232425
Fiscal yearValueYoY
FY2025$123.7M+63.5%
FY2024$75.6M—
FY2023$0—

Source: SEC XBRL filings · For reference only · Not investment advice

More GLUE financial trends

GLUE Net incomeGLUE Net marginGLUE Gross profitGLUE Gross marginGLUE Operating incomeGLUE Operating marginGLUE Operating cash flowGLUE Free cash flowGLUE Capital expendituresGLUE Return on equityGLUE Stock buybacksGLUE Dividends paidGLUE Total assetsGLUE Total liabilitiesGLUE Shareholders’ equityGLUE overview →